Biogen (BIIB)
(Delayed Data from NSDQ)
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$204.76 USD
-0.06 (-0.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $204.61 -0.15 (-0.07%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Zacks News
Biogen (BIIB) Q2 Earnings & Sales Beat Estimates
by Zacks Equity Research
Biogen (BIIB) beats estimates for both earnings and sales in the second quarter. It lifts sales and earnings expectations for the year. Shares rise in pre-market trading
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q2?
by Zacks Equity Research
While sales of Biogen's (BIIB) MS franchise are expected to decline in the second quarter of 2019, Spinraza U.S. sales may improve.
Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amgen & Novartis' Alzheimer Studies End in Another Failure
by Zacks Equity Research
Amgen (AMGN) and Novartis (NVS) discontinue two Alzheimer's disease studies. Alzheimer's has always been a highly challenging area with many studies failing.
Will Patent Woes Boost Pharma Stock Megamergers Further?
by Nilanjan Banerjee
With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.
Top Analyst Reports for Boeing, 3M & U.S. Bancorp
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Boeing (BA), 3M (MMM) and U.S. Bancorp (USB).
Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Biogen (BIIB) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Atara Reports Initial Data for Multiple Sclerosis Candidate
by Zacks Equity Research
Atara (ATRA) announces initial ATA188 phase I safety results for patients with progressive MS.
5 ROE Stocks to Buy as Trade Talks Resume Ahead of G20 Summit
by Supriyo Bose
ROE is often used to compare the profitability of a company with other firms in the industry - the higher, the better.
3 Reasons Why Growth Investors Shouldn't Overlook Biogen (BIIB)
by Zacks Equity Research
Biogen (BIIB) is well positioned to outperform the market, as it exhibits above-average growth in financials.
The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Union Pacific, NextEra, Biogen, Humana and Marathon
Top Stock Reports for Union Pacific, NextEra & Biogen
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Union Pacific (UNP), NextEra (NEE) and Biogen (BIIB).
AstraZeneca Gives Detailed Data From Calquence Leukemia Study
by Zacks Equity Research
AstraZeneca's (AZN) Calquence monotherapy prolongs progression-free survival significantly in relapsed or refractory CLL patients compared to Roche's Rituxan.
Biogen (BIIB) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Biogen (BIIB) closed the most recent trading day at $230.86, moving +0.19% from the previous trading session.
Biotech Stock Roundup: Celgene Submits MS Drug to FDA, INSY & CBAY Crash
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Biogen (BIIB) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Biogen (BIIB) closed the most recent trading day at $227.33, moving +1.33% from the previous trading session.
Celgene's Filing for Ozanimod Accepted for Review in US/EU
by Zacks Equity Research
The FDA and the EMA accept Celgene's (CELG) multiple sclerosis candidate, ozanimod, for review.
Biogen Reports Interim Phase III Data on Diroximel Fumarate
by Zacks Equity Research
Biogen (BIIB) announces new interim results from phase III EVOLVE-MS-1 study, which showed that the diroximel fumarate was generally well tolerated in people with relapsing MS.
Roche (RHHBY) Up 6.3% YTD on Strong Demand for New Drugs
by Zacks Equity Research
Roche's (RHHBY) performance has been strong in the year so far, driven by solid growth of Ocrevus, Perjeta, Tecentriq and Hemlibra.
PDL BioPharma's Royalties Help, Heavy Partner Reliance Hurts
by Zacks Equity Research
PDL BioPharma (PDLI) aims to acquire and manage high-yielding assets and maximize shareholder value. Blindly falling back on partners for royalties is a persistent concern.
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Biogen (BIIB) closed at $223.40, marking a -0.95% move from the previous day.
Celgene's Revlimid-Rituximab Combo Gets FDA Nod for Lymphoma
by Zacks Equity Research
Celgene's (CELG) Revlimid in combination with a rituximab product gets FDA approval for the treatment of adult patients with previously treated follicular lymphoma or marginal zone lymphoma.
Roche Gets FDA Nod for Expansion of Cobas 6800/8800 Systems
by Zacks Equity Research
Roche (RHHBY) gets FDA clearance for the expansion of its leading testing menu.
Biogen (BIIB) Down 0.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Biogen (BIIB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Earnings Preview: Veeva (VEEV), Palo Alto Networks (PANW), Workday (WDAY)
by Benjamin Rains
Let's look at what investors should expect from some of the more notable tech companies still left to report: Veeva Systems Inc. (VEEV), Workday, Inc. (WDAY), and Palo Alto Networks, Inc. (PANW).